


ASET Platform

Avian System for Evaluating Therapeutics




Innovascreen Inc.

Innovascreen is an ideal partner for any Pharmaceutical or Biotech company engaged in early-stage research and development of novel therapeutics. With two proprietary platforms, the ASET Platform for early preclinical research and the Fusogenix Platform for drug delivery, Innovascreen has the tools to accelerate the drug development process. Whether combined with internal programs or partnered with external compounds, these platforms have the opportunity to add significant value to preclinical therapeutic opportunities.

The ASET Platform

The Avian System for Evaluating Therapeutics (ASET) Platform is a proprietary system, combining a novel animal model and powerful imaging technology, to screen and validate early-stage therapeutic candidates. The key to our platform is a proprietary non-invasive, intravital imaging system to monitor and quantify host cells, tumor cells and drug in real time. The combination of these innovative technologies into the ASET Platform allows us to visualize and directly measure the results of a pharmaceutical therapy *in vivo* in a substantially reduced time compared to conventional *in vivo* models.



With the help of some innovative nanotechnology, the ASET platform can provide richly detailed 3D time-lapse imagery of up to six distinct molecular features in real time. Our *in vivo* assays include Angiogenesis, Metastasis, Cell Migration, Tumor Growth, Vascular Permeability and Molecular Pharmacokinetics.

The ASET platform allows the screening of compounds faster and at a lesser cost than conventional animal models while providing stronger, more significant results. For this reason, the ASET platform is a compelling choice to identify and validate your leads with high efficacy and low toxicity earlier in the development pipeline.